Specifications, dosage forms and applicable patient types of Mobosetinib (Anvili)

Mobocertinib is an oral small molecule tyrosine kinase inhibitor (TKI) that mainly targets EGFR exon 20 insertion mutations (EGFR Exon20ins) are designed for patients with non-small cell lung cancer (NSCLC). As one of the first targeted drugs specifically for this type of mutation, mobosetinib has filled the gap in the limited efficacy of traditional EGFR-TKI against Exon20 insertion mutations, providing patients with precise treatment options.

In terms of dosage form and specifications, mobosetinib is currently available in capsule oral dosage form . The common specifications are 40mg capsules. The recommended dosage is usually 160mg taken orally once a day, that is, patients need to take 40mg capsules 4 capsules daily. The specific dosage needs to be adjusted by the doctor according to the patient's tolerance and adverse reactions. The oral method is convenient, can reduce the burden of frequent infusions on patients, and is conducive to long-term maintenance treatment.

In terms of applicable population, mobosetinib is mainly used for patients with locally advanced or metastatic non-small cell lung cancer who have progressed after previously receiving platinum-containing chemotherapy EGFR Exon20ins mutation. Since this mutation has a low proportion among conventional EGFR mutations, patients must undergo genetic testing before taking medication to determine whether there is an Exon20 insertion mutation to ensure the accuracy of targeted drugs. The drug is not recommended for patients with negative test results.

Overall, the clinical value of mobosetinib lies in providing a new oral treatment option for special mutant lung cancer patients for whom traditional therapies have limited efficacy . The dosage form is simple and the course of treatment is relatively standardized. However, due to the possibility of adverse reactions such as diarrhea, rash, and cardiotoxicity, patients need to be closely followed up during use and adjust the dosage or provide supportive treatment under the guidance of a doctor to ensure a balance between efficacy and safety.

Reference link:https://www.drugs.com